Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Bokemeyer

Showing results (361-370 of 664) with videos related to

Pageof 67
Sort By:
Oncoimmunology|November 20, 2019
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancerHauke Stamm, Leticia Oliveira-Ferrer, Eva-Maria Grossjohann, et al.
Marine Drugs|October 26, 2022
Cytotoxic N-Methylpretrichodermamide B Reveals Anticancer Activity and Inhibits P-Glycoprotein in Drug-Resistant Prostate Cancer CellsSergey A Dyshlovoy, Tobias Busenbender, Jessica Hauschild, et al.
European Journal of Internal Medicine|March 25, 2025
Excess mortality of critically ill patients aged ≥90 years in intensive care units: A retrospective cohort studyJan Frederic Weller, Kevin Roedl, Rikus Daniels, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2008
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on primingDjordje Atanackovic, Nasser K Altorki, Yanran Cao, et al.
Experimental Hematology|April 27, 2005
Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinibUlrike Hartmann, Stefan Balabanov, Patrick Ziegler, et al.
Cancers|June 10, 2022
Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective TreatmentSusanne Ghandili, Philipp H von Kroge, Marcel Simon, et al.
Plos One|July 11, 2014
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapseJan K Hennigs, Julia Müller, Matti Adam, et al.
Applied Health Economics and Health Policy|May 24, 2021
Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology TherapiesJennifer G Gaultney, Jacoline C Bouvy, Richard H Chapman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trialMaria De Santis, Alexander Becherer, Carsten Bokemeyer, et al.
Journal of Proteomics|November 26, 2013
Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancerSergey A Dyshlovoy, Simone Venz, Larisa K Shubina, et al.
Pageof 67

Showing results (361-370 of 664) with videos related to

Sort By:
Pageof 67
Oncoimmunology|November 20, 2019
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancerHauke Stamm, Leticia Oliveira-Ferrer, Eva-Maria Grossjohann, et al.
Marine Drugs|October 26, 2022
Cytotoxic N-Methylpretrichodermamide B Reveals Anticancer Activity and Inhibits P-Glycoprotein in Drug-Resistant Prostate Cancer CellsSergey A Dyshlovoy, Tobias Busenbender, Jessica Hauschild, et al.
European Journal of Internal Medicine|March 25, 2025
Excess mortality of critically ill patients aged ≥90 years in intensive care units: A retrospective cohort studyJan Frederic Weller, Kevin Roedl, Rikus Daniels, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2008
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on primingDjordje Atanackovic, Nasser K Altorki, Yanran Cao, et al.
Experimental Hematology|April 27, 2005
Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinibUlrike Hartmann, Stefan Balabanov, Patrick Ziegler, et al.
Cancers|June 10, 2022
Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective TreatmentSusanne Ghandili, Philipp H von Kroge, Marcel Simon, et al.
Plos One|July 11, 2014
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapseJan K Hennigs, Julia Müller, Matti Adam, et al.
Applied Health Economics and Health Policy|May 24, 2021
Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology TherapiesJennifer G Gaultney, Jacoline C Bouvy, Richard H Chapman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trialMaria De Santis, Alexander Becherer, Carsten Bokemeyer, et al.
Journal of Proteomics|November 26, 2013
Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancerSergey A Dyshlovoy, Simone Venz, Larisa K Shubina, et al.
Pageof 67